Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $126.4 million.

  • Capricor Therapeutics' Liabilities and Shareholders Equity rose 3602.58% to $126.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $584.3 million, marking a year-over-year increase of 14404.14%. This contributed to the annual value of $170.5 million for FY2024, which is 19025.8% up from last year.
  • According to the latest figures from Q3 2025, Capricor Therapeutics' Liabilities and Shareholders Equity is $126.4 million, which was up 3602.58% from $133.6 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Liabilities and Shareholders Equity ranged from a high of $170.5 million in Q4 2024 and a low of $37.2 million during Q3 2023
  • For the 5-year period, Capricor Therapeutics' Liabilities and Shareholders Equity averaged around $71.3 million, with its median value being $53.9 million (2023).
  • In the last 5 years, Capricor Therapeutics' Liabilities and Shareholders Equity plummeted by 3110.77% in 2023 and then surged by 24894.96% in 2025.
  • Quarter analysis of 5 years shows Capricor Therapeutics' Liabilities and Shareholders Equity stood at $41.3 million in 2021, then increased by 21.21% to $50.1 million in 2022, then grew by 17.25% to $58.7 million in 2023, then surged by 190.26% to $170.5 million in 2024, then decreased by 25.83% to $126.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $126.4 million for Q3 2025, versus $133.6 million for Q2 2025 and $153.8 million for Q1 2025.